Neurologic complications of bone marrow transplantation

Neurologic Clinics

Volumn 21, Issue 1, 2003, Pages 319-352

  Krouwer, Hendrikus G J ^a   Wijdicks, Eelco F M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SOLID TUMOR;

BONE MARROW TRANSPLANTATION; BRAIN; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM INFECTIONS; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 0037310930     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(02)00036-1     Document Type: Review

References (210)

1. Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nature Reviews: Cancer 2002;2:231-8.
2. Fine HA, Antman KH. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant 1992;10:315-21.
3. Millot F, Delval O, Giraud C, et al. High-dose chemotherapy with hematopoietic stem cell transplantation in adults with bone marrow relapse of medulloblastoma: report of two. Bone Marrow Transplant 1999;24:1347-9.
4. Gururangan S, Dunkel I, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue for patients with recurrent malignant brain tumors. J Clin Oncol 1998;16:2486-93.
5. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995;16:1-6.
6. Burt RK, Traynor AN, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-14.
7. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001;57:62-8.
8. Staba MJ, Goldman S, Johnson FL, et al. Allogeneic bone marrow transplantation for Alexander's disease. Bone Marrow Transplant 1997;20:247-9.
9. Mahmood A, Lu D, Li Y, et al. Intracranial bone marrow transplantation after traumatic brain injury improving functional outcome in adult rats. J Neurosurg 2001; 94:589-95.
10. Li Y, Chen J, Wang L, et al. Treatment of stroke in rates with intracarotid administration of marrow stromal cells. Neurology 2001;56:1666-72.
11. Krivit W, Lipton ME, Lockman LA, et al. Prevention of deterioration in metachromatic leukodystrophy by bone marrow transplantation. Am J Med Sci 1987;294:80-5.
12. Ratanatharathorn V, Ayash L, Lazarus HM. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121-9.
13. Snider S, Bashir R, Bierman P. Neuologic complications after high-dose chemotherapy and autologous bone marrow transplantation for Hodgkin's disease. Neurology 1994; 44:681-4.
14. Gallardo D, Gerra C, Berlanga JJ, et al. Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:1135-9.
15. Graus F, Saiz A, Sierra J, et al. Neurologic complications of autologous and allogeneic bone marrow transplantation in patient with leukemia: a comparative study. Neurology 1996;46:1004-9.
16. Antonini G, Ceschin V, Morino S, et al. Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology 1998; 50:1441-5.
17. Den Brabander C, Cornelissen J, Sillevis Smitt PAE, et al. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation form alternative donors. J Neurol Neurosurg Psychiatry 2000;68:36-40.
18. Patchell RA, White III CL, Clark AW, et al. Neurologic complications of bone marrow transplantation. Neurology 1985;35:300-6.
19. Mohrmann RL, Mah V, Vinters HV. Neuropathologic findings after bone marrow transplantation. Hum Pathol 1990;21:630-9.
20. Bleggi-Torres LF, deMedeiros BC, Werner B, et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant 2000; 25:301-7.
21. Gordon B, Lyden E, Lynch J, et al. Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients. Bone Marrow Transplant 2000;25:79-83.
22. Jackson SR, Tweeddale MG, Barnett MJ, et al. Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors. Bone Marrow Transplant 1998;21:697-704.
23. Openshaw H, Slatkin NE. Neurological complications. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd edition. Malden (MA): Blackwell Science; 1999. p. 659-73.
24. Forman SJ, Openshaw H. Bone marrow (hematopoietic cell) transplantation. In: Wijdicks EFM, editor. Neurologic complications in organ transplant recipients. Boston: Butterworth-Heinemann; 1999. p. 45-54.
25. Haire WD. The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation. Semin Thromb Hemost 1999;25(2):223-37.
26. Haire WD, Stephens LC, Ruby EI. Systemic inflammatory response syndrome (SIRS), sepsis and organ dysfunction in bone marrow transplantation (BMT) [abstract]. Blood 1996;88(Suppl 1):255b.
27. McGuire TR, Bociek GR, Pavletic Z, et al. Organ dysfunction following stem cell transplantation: relationship to plasma cytokine concentrations. Bone Marrow Transplant 2001;28:889-93.
28. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after gone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-67.
29. Guinan EC, Tarbell NJ, Niemeyer CM, et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988;72:451-5.
30. Rabinowe SN, Soiffer RJ, Tarbell NJ, et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991;77:1837-44.
31. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994;14:495-504.
32. Schriber JR, Herzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:126-33.
33. Elliott MA, Nichols WL. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc 2001;76:1154-62.
34. Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991;9:679-93.
35. Miller L, Link MP, Bologna S, et al. Cerebellar atrophy caused by high-dose cytosine arabinoside: CT and MR findings. AJR Am J Roentgenol 1989;152:343-4.
36. Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815-9.
37. Anderson NR, Tandon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer 1991;68: 72-5.
38. Curtin JP, Koonings PP, Gutierrez M, et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991;42:193-6.
39. Perry JR, Warner E. Transient enephalopathy after paclitaxel (Taxol) infusion. Neurology 1996;46:1596-9.
40. Sullivan KM, Storb R, Shulma M, et al. Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 1982;97:182-9.
41. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cisplatinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 1980;45:764-6.
42. Ebner F, Ranner G, Slavc I, et al. MR findings in methotrexate-induced CNS abnormalities. Am J Neuroradiol 1989;10:959-64.
43. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989;32:770-5.
44. Wijdicks EFM. Neurologic manifestations of immunosuppressive agents. In: Wijdicks EFM, editor. Neurologic complications in organ transplant recipients. Boston: Butterworth- Heinemann; 1999. p. 127-40.
45. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984;101:92-104.
46. Frytak S, Moertel CG, Childs DS, et al. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978;88:361-2.
47. Kusumi RK, Plouffe JF, Wyatt RH, et al. Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med 1980;93:59-60.
48. Woodruff BK, Wijdicks EFM, Marshall WF. Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med 2002;346(1):68-9.
49. Wade JC, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983;98:921-5.
50. Cohen SMZ, Minkove JA, Zebley JW, et al. Severe but reversible neurotoxicity from acyclovir. Ann Intern Med 1984;100:920.
51. Adair JC, Gold M. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J 1994;87(12):1227-31.
52. Blohm MEG, Nurnberger W, Aulich A, et al. Reversible brain MRI changes in acyclovir neurotoxicity. Bone Marrow Transplant 1997;19:1049-51.
53. Davis CL, Springmeyer S, Gmerek BJ, et al. Central nervous system side effects of ganciclovir. N Engl J Med 1990;332:933-4.
54. Devinsky O, Lemann W, Evans AI, et al. Akinetic mutism in a bone marrow transplant recipient following total-body irradiation and amphotericin B chemoprophylaxis. Arch Neurol 1987;44:414-7.
55. Plevak DJ, Wijdicks EFM. Failure to awaken and acute disturbances of consciousness. In: Wijdicks EFM, editor. Neurologic complications in organ transplant recipients. Boston: Butterworth-Heinemann; 1999. p. 63-89.
56. Antunes NL, Boulad F, Prasad V, et al. Rolandic encephalopathy and epilepsia partialis continua following bone marrow transplant. Bone Marrow Transplant 2000;26:917-9.
57. Walters MC, Sullivan KM, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995:85(4):879-84.
58. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
59. De La Camara R, Tomas JF, Figuera A, et al. High dose busulfan and seizures. Bone Marrow Transplant 1991;7:363-4.
60. Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989;7:179-85.
61. Openshaw H, Slatkin NE. Differential diagnosis of neurological complications in bone marrow transplantation. The Neurologist 1995;1:191-206.
62. Wszolek JK, Steg RE, Wydicks EFM. Seizures. In: Wijdicks EFM, editor. Neurologic complications in organ transplant recipients. Boston: Butterworth-Heinemann; 1999. p. 107-25.
63. Tolkoff-Rubin NE, Hovingh GH, Rubin RH. Central nervous system infections., In: Wijdicks EFM, editor. Neurologic complications in organ transplant recipients. Boston: Butterworth-Heinemann; 1999. p. 141-68.
64. Long SG, Leyland MJ, Milligan DW. Listeria meningitis after bone marrow transplantation. Bone Marrow Transplant 1993;12:537-9.
65. Abraham J, Bilgrami S, Dorsky D, et al. Stomatococcus mucilaginosus meningitis in a patient with multiple myeloma following autologous stem cell transplantation. Bone Marrow Transplant 1997;19:639-41.
66. D'Antonio D, DiBartolomeo D, Iacone A, et al. Meningitis due to penicillin-resistant Streptococcus pneumoniae in patients with chronic graft-versus-host disease. Bone Marrow Transplant 1992;9:299-300.
67. Feingold JM, Abraham J, Bilgrami S, et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Bone Marrow Transplant 1998; 22:297-300.
68. Baddley JW, Moser SA, Sutton DA, et al. Microascus cinereus (Anamorph Scopulariopsis) brain abscess in a bone marrow recipient. J Clin Microbiol 2000;38:395-7.
69. Davis D, Henslee J, Markesbery WR. Fatal adenovirus meningoencephalitis in a bone marrow transplant patient. Ann Neurol 1988;23:385-9.
70. Dellemijn PLI, Brandenburg A, Niesters HGM, et al. Successful treatment with ganciclovir of presumed Epstein-Barr meningo-encephalitis following bone marrow transplant. Bone Marrow Transplant 1995;16:311-2.
71. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:44-9.
72. Tauro S, Toh V, Osman H, et al. Varicella zoster meningoencephalitis following treatment for dermatomal zoster in an alloBMT patient. Bone Marrow Transplant 2000;26:795-6.
73. Bosi A, Zazzi M, Amantini A, et al. Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bone Marrow Transplant 1998;22:285-8.
74. Kimberlin DW, Whitley RJ. Human herpes virus-6: neurologic implications of a newly-described viral pathogen. J Neurovirol 1998;4:474-85.
75. Drobyski WR, Knox KK, Majewski D, et al. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med 1994;330:1356-60.
76. Mookerjee BP, Vogelsang G. Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant 1997; 20:905-6.
77. Cole PE, Stiles J, Boulad R, et al. Successful treatment of human herpes virus 6 encephalitis in bone marrow transplant recipients. Clin Infect Dis 1998;27:653-4.
78. Rieux C, Cautheret-Dejean A, Challine-Lehmann C, et al. Human herpes virus-6 meningoencephalitis in a recipient of an unrelated allogeneic bone marrow transplantation. Transplantation 1998;65:1408-11.
79. Tsujimura H, Iseki T, Date Y, et al. Human herpesvirus-6 encephalitis after bone marrow transplantation: magnetic resonance imaging could identify the involved sites of encephalitis. Eur J Haematol 1998;61:284-5.
80. Wang FZ, Linde A, Hagglund H, et al. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 1999;28:562-8.
81. Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients. Transplantation 2000;69:2474-9.
82. Mitchell RB, Wagner JE, Karp JE, et al. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med 1988;85:662-7.
83. Tse N, Cederbaum S, Glaspy JA. Hyperammonemia following allogeneic bone marrow transplantation. Am J Hematol 1991;38:140-1.
84. Davies SM, Szabo E, Wagner JE, et al. Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant 1996;17:1119-25.
85. Leonard JV, Kay JDS. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukemia with asparaginase. Lancet 1986;1(8473):162-3.
86. Blindauer KA, Harrington G, Morris GL, et al. Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 1998;51:292-5.
87. Majolino I, Caponetto A, Scime R, et al. Wernicke-like encephalopathy after autologous bone marrow transplantation. Haematologica 1990;75:282-4.
88. Bleggi-Torres LF, deMedeiros BC, Ogasawara VSA, et al. Iatrogenic Wernicke's encephalopathy in allogeneic bone marrow transplantation: a study of eight cases. Bone Marrow Transplant 1997;20:391-5.
89. Doherty MJ, Watson NF, Uchino K, et al. Diffusion abnormalities in patients with Wernicke encephalopathy. Neurology 2002;58:655-7.
90. Bleggi-Torres LF, Werner B, Gasparetto EL, et al. Intracranial hemorrhage following bone marrow transplantation: an autopsy study of 58 patients. Bone Marrow Transplant 2002;29:29-32.
91. Patchell RA, White CL III, Clark AW, et al. Nonbacterial thrombotic endocarditis in bone marrow transplant patients. Cancer 1985;55:631-5.
92. Nogueira RG, Sheen VL. Herpes zoster ophthalmicus followed by contralateral hemiparesis. N Engl J Med 2002;346:1127.
93. Teksam M, Casey SO, Michel E, et al. Subarachnoid hemorrhage associated with cyclosporine A neurotoxicity in a bone-marrow transplant recipient. Neuroradiology 2001;43:242-5.
94. Colosimo M, McCarthy N, Jayasinghe R, et al. Diagnosis and management of subdural hematoma complicating bone marrow transplantation. Bone Marrow Transplant 2000;25:549-52.
95. Pomeranz S, Naparstek E, Ashkenazi E, et al. Intracranial haematomas following bone marrow transplantation. J Neurol 1994;241:252-6.
96. DeLone DR, Goldstein RA, Petermann G, et al. Disseminated aspergillosis involving the brain: distribution and imaging characteristics. Am J Neuroradial 1999;20:1597-604.
97. Harvey CJ, Peviket AJ, Miszkiel K, et al. MR angiographic diagnosis of cerebral venous sinus thrombosis following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:791-5.
98. Bertz H, Laubenberger J, Steinfurth G, et al. Sinus venous thrombosis: an unusual cause for neurologic symptoms after bone marrow transplantation under immunosuppression. Transplantation 1998;66:241-4.
99. Mori A, Tanaka J, Kobayashi S, et al. Fatal cerebral hemorrhage associated with cyclosporin-A/FK-506-related encephalopathy after allogeneic bone marrow transplantation. Ann Hematol 2000;79:588-92.
100. Richard S, Seigneur M, Blann A, et al. Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1996;18:955-9.
101. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986;4:1405-17.
102. Jerman MR, Fick RB Jr. Nonbacterial thrombotic endocarditis associated with bone marrow transplantation. Chest 1986;90(6):919-22.
103. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985;64:16-35.
104. Gordon BG, Saving KL, McCallister JA, et al. Cerebral infarction associated with protein C deficiency following allogeneic bone marrow transplantation. Bone Marrow Transplant 1991;8:323-5.
105. Kaufman PA, Jones RB, Greenberg CS, et al. Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Cancer 1990;66:515-21.
106. Gordon B, Haire W, Kessinger A, et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991;8:497-502.
107. Qasim W, Gerritsen B, Veys P, Anticardiolipin antibodies and thromboembolism after BMT. Bone Marrow Transplant 1998;21:845-7.
108. Tschuchnigg M, Bradstock KF, Koutts J, et al. A case of thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990;5:61-3.
109. Kalhs P, Brugger S, Schwarzinger I, et al. Microangiopathy following allogeneic marrow transplantation. Transplantation 1995;60(9):949-57.
110. Padovan CS, Bise K, Hahn J, et al. Angiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke 1999;30:1651-6.
111. Padovan CS, Gerbitz A, Sostak P, et al. Cerebral involvement in graft-versus-host disease after murine bone marrow transplantation. Neurology 2001;56:1106-8.
112. Maschke M, Dietrich U, Prumbaum M, et al. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 1999;23:1167-76.
113. Hagensee ME, Bauwens JE, Kjos B, et al. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994;19:402-8.
114. Choucino C, Goodman SA, Greer JP, et al. Nocardial infections in bone marrow transplant recipients. Clin Infect Dis 1996;23:1012-9.
115. Elliott MA, Tefferi A, Marshall WF, et al. Disseminated nocardiosis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20:425-6.
116. Campos A, Vaz CP, Campilho F, et al. Central nervous system (CNS) tuberculosis following allogeneic stem cell transplantation. Bone Marrow Transplant 2000;25:567-9.
117. Martino R, Martinez C, Brunet S, et al. Tuberculosis bone marrow transplant recipients: report of two cases and review of the literature. Bone Marrow Transplant 1996;18:809-12.
118. Aljurf M, Gyger M, Alrajhi A, et al. Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients. Bone Marrow Transplant 1999;24:551-4.
119. Harris DE, Enterline DS. Fungal infections of the central nervous system. Neuroimaging Clin N Am 1997;7:187-98.
120. Miaux Y, Ribaud P, Williams M, et al. MR of cerebral aspergillosis in patients who have had bone marrow transplantation. AJNR Am J Neuroradiol 1995;16:555-62.
121. Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994;62:155-9.
122. Khoury H, Adkins D, Miller G, et al. Resolution of invasive central nervous system aspergillosis in a transplant recipient. Bone Marrow Transplant 1997;20:179-80.
123. Baslar Z, Soysal T, Hanci M, et al. Successfully treated invasive central nervous system aspergillosis in an allogeneic stem cell transplant recipient. Bone Marrow Transplant 1998;22(4):404-5.
124. Nenoff P, Kellermann S, Schober R, et al. Rhinocerebral zygomycosis following bone marrow transplantation in chronic myelogenous leukaemia. Report of a case and review of the literature. Mycoses 1998;41:365-72.
125. Brinkman K, Debast S, Sauerwein R, et al. Toxoplasma retinitis/encephalitis 9 months after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;21: 635-6.
126. Foot ABM, Garin YJF, Ribaud P, et al. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 1994;14:241-5.
127. Slavin MA, Meyers JD, Remington JS, et al. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 1994;13: 549-57.
128. Derouin F, Devergie A, Auber P, et al. Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis 1992;15:267-70.
129. Tefferi A, O'Neill BP, Inwards DJ. Late-onset cerebral toxoplasmosis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;21:1285-6.
130. Dietrich U, Maschke M, Dorfler A, et al. MRI of intracranial toxoplasmosis after bone marrow transplantation. Neuroradiology 2000;42:14-8.
131. Chandrasekar PH, Momin F. Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of literature. Bone Marrow Transplant 1997;19:685-9.
132. Khoury H, Adkins D, Brown R, et al. Successful treatment of cerebral toxoplasmosis in a marrow transplant recipient: contribution of a PCR test in diagnosis and early detection. Bone Marrow Transplant 1999;23:409-11.
133. Seong DC, Przepiorka D, Bruner JM, et al. Leptomeningeal toxoplasmosis after allogeneic marrow transplantation. Am J Clin Oncol 1993;16:105-8.
134. Bleggi-Torres LF, deMedeiros BC, Werner B. Unusual presentation of cerebral toxoplasmosis after BMT. Bone Marrow Transplant 1999;23:855-6.
135. Cordonnier C, Feuilhade F, Vernant JP, et al. Cytomegalovirus encephalitis occurring after bone marrow transplantation. Scand J Haematol 1983;31:248-52.
136. Mesquita R, Parravicini C, Bjorkholm M, et al. Macrophage association of polyomavirus in progressive multifocal leukoencephalopathy: an immunohistochemical and ultrastructural study. APMIS 1992;100:993-1000.
137. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993;119:207-14.
138. O'Shaughnessy D, Goldman JM, Roddie M, et al. Clinicopathological conference. BMJ 1994;309:262-5.
139. Owen RG, Patmore RD, Smith GM, et al. Cytomegalovirus-induced T-cell proliferation and the development of progressive multifocal leucoencephalopathy following bone marrow transplantation. Br J Haematol 1995;89:196-8.
140. Seong D, Bruner JM, Lee KH, et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. Clin Infect Dis 1996;23:402-3.
141. Przepiorka D, Jaeckle KA, Birdwell RR, et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 1997;20:983-7.
142. Re D, Bamborschke S, Feiden W, et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 1999;23:295-8.
143. Coppo P, Laporte JPh, Aoudjhane M, et al. Progressive multifocal leucoencephalopathy with peripheral demyelinating neuropathy after autologous bone marrow transplantation for acute myeloblastic leukemia (FAB5). Bone Marrow Transplant 1999;23:401-3.
144. Wszolek ZK, Steg RE, Armitage JO. Complex partial status epilepticus after bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:637-8.
145. Penn I. De novo malignant lesions of the central nervous system. In: Wijdicks EFM, editor. Neurologic complications in organ transplant recipients. Boston: Butterworth-Heinemann; 1999. p. 217-27.
146. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000;18:348-57.
147. Curtis RE, Rowlings PA, Deeg H, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897-904.
148. Small SL, Fukui MB, Bramblett GT, et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506). Ann Neurol 1996;40:575-80.
149. Shah AK. Cyclosporine. A neurotoxicity among bone marrow recipients. Clin Neuropharmacol 1999;22:67-73.
150. Saito J, Kami M, Taniguchi F, et al. Unilateral papilledema after bone marrow transplantation. Bone Marrow Transplant 1999;23:963-5.
151. Openshaw H, Slatkin NE, Smith E. Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir. Bone Marrow Transplant 1997;19:503-5.
152. Openshaw H. Eye movement abnormality associated with cyclosporin. J Neurol Neurosurg Psychiat 2001;70:809.
153. Apsner R, Schulenburg A, Steinhoff N, et al. Cyclosporin A-induced ocular flutter after bone marrow transplantation. Bone Marrow Transplant 1997;20:255-6.
154. Rubin AL, Kang H. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology 1987;37:1072-6.
155. Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991; 8:393-401.
156. Steg RE, Kessinger A, Wszolek ZK. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. Bone Marrow Transplant 1999;23: 959-62.
157. Misawa A, Takeuchi Y, Hibi S, et al. FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25:331-4.
158. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000;26:985-91.
159. Takahata M, Hashino S, Izumiyama K, et al. Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. Bone Marrow Transplant 2001;28:713-5.
160. Takeguchi N, Ishimura K, Koike M, et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immuno-suppressants FK506 and cyclosporine. Transplantation 1993;3:646-50.
161. Shbarou RM, Chao NJ, Morgenlander JC. Cyclosporin A-related cerebral vasculopathy. Bone Marrow Transplant 2000;26:801-4.
162. Jarosz JM, Howlett DC, Cox TCS, et al. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. Neuroradiology 1997;39:711-5.
163. Furukawa M, Terae S, Chu BC, et al. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging. Neuroradiology 2001;43:615-21.
164. Higman MA, Port JD, Beauchamp NJ, et al. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant 2000;26:797-800.
165. Atkinson K, Biggs J, Darveniza P, et al. Spinal cord and cerebellar-like syndromes associated with the use of cyclosporine in human recipients of allogeneic marrow transplants. Transplant Proc 1985;17:1673-5.
166. Openshaw H, Slatkin NE, Parker PM, et al. Immune-mediated myelopathy after allogeneic marrow transplantation. Bone Marrow Transplant 1995; 15:633-6.
167. Richard Fruchtman S, Scigliano E, et al. An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia. Bone Marrow Transplant 2000;26:1225-8.
168. Chao MWT, Wirth A, Ryan G, et al. Radiation myelopathy following transplantation and radiotherapy for non-Hodgkin's lymphoma. Int J Radial Oncol Biol Phys 1998; 41:1057-61.
169. Schwartz DL, Schechter GP, Seltzer S, et al. Radiation myelitis following allogeneic stem cell transplantation and consolidation radiotherapy for non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;26:1355-9.
170. Tahsildar HI, Remler BF, Creger RJ, et al. Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients. J Neurooncol 1996;27:241-50.
171. Azuno Y, Yaga K, Kaneko T. Chronic graft-versus-host disease and seizure. Blood 1998;91:2626-7.
172. Rouah E, Gruber R, Shearer W, et al. Graft-versus-host disease in the central nervous system. Am J Clin Pathol 1988;89:543-6.
173. Padovan CS, Yousry TA, Schleuning M, et al. Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation. Ann Neurol 1998;43:627-33.
174. Bolton CF, Young GB. Critical illness polyneuropathy. Curr Opin Neurol 2000;2:489-98.
175. Zifko UA. Long-term outcome of critical illness polyneuropathy. Muscle Nerve 2000; Suppl:549-52.
176. Zochodne DW, Ramsay DA, Saly V, et al. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994;17:285-92.
177. Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical, electromyographic and pathological aspects. Ann Neurol 1996;40:645-54.
178. Samuelsson J, Zackrisson H, Tokics L, et al. Acute quadriplegic myopathy following autologous peripheral blood stem cell transplantation for breast cancer. Bone Marrow Transplant 1999;23:835-7.
179. Imrie KR, Couture F, Turner CC, et al. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 1994;13:77-9.
180. Boogerd W, ten Bokkel Huinink WW, Dalesio O, et al. Cisplatin induced neuropathy: central, peripheral and autonomic involvement. J Neurooncol 1990;9:255-63.
181. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-73.
182. Hilkens PHE, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996;46:104-8.
183. New PZ, Jackson CE, Rinaldi D, et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11.
184. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968;31:543-51.
185. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984;120:338-41.
186. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
187. Johnson NT, Crawford SW, Sargur M. Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation. Bone Marrow Transplant 1987;2:203-7.
188. Openshaw H, Slatkin NE, Stein AS, et al. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996;78:1899-905.
189. Greenspan A, Deeg HJ, Cottler-Fox M, et al. Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease. Bone Marrow Transplant 1990;5:349-52.
190. Openshaw H, Hinton DR, Slatkin NE, et al. Exacerbation of inflammatory demyelinating polyneuropathy after bone marrow transplantation. Bone Marrow Transplant 1991;7:411-4.
191. Eliashiv S, Brenner T, Abramsky O, et al. Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation. Bone Marrow Transplant 1991; 8:315-7.
192. Bashir RM, Bierman P, McComb R. Inflammatory peripheral neuropathy following high dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1992;10:305-6.
193. Hagensee ME, Benyunes M, Miller JA, et al. Campylobacter jejuni bacteremia and Guillain-Barre syndrome in a patient with GVHD after allogeneic BMT. Bone Marrow Transplant 1994;13:349-51.
194. Perry A, Mehta J, Iveson T, et al. Guillain-Barre syndrome after bone marrow transplantation. Bone Marrow Transplant 1994;14:165-7.
195. Wen PY, Alyea EP, Simon D, et al. Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 1997;49:1711-4.
196. Griggs JJ, Commichau CS, Rapoport AP, et al. Chronic inflammatory demyelinating polyneuropathy in non-Hodgkin's lymphoma. Am J Hematol 1997;54: 332-4.
197. Amato AA, Barohn RJ, Sahenk Z, et al. Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology 1993;43:1513-8.
198. Gabriel CM, Goldman JM, Lucas S, et al. Vasculitic neuropathy in association with chronic graft-versus-host disease. J Neurol Sci 1999;168:68-70.
199. Openshaw H. Peripheral neuropathy after bone marrow transplantation. Biol Blood Marrow Transplant 1997;3:202-9.
200. Parker PM, Openshaw H, Forman SJ. Myositis associated with graft-versus-host disease. Curr Opin Rheumatol 1997;9:513-9.
201. Zaja F, Russo D, Silvestri F, et al. Myasthenia gravis after allogeneic bone marrow transplantation: a case report. Bone Marrow Transplant 1995;15:649-50.
202. Mackey JR, Desai S, Larratt L, et al. Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature. Bone Marrow Transplant 1997;19:939-42.
203. Baron F, Sadzot B, Wang F, et al. Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;22:197-200.
204. Koski SL, Mackey JR, Mackey DS. Myasthenia gravis post-allogeneic bone marrow transplantation revisited. Bone Marrow Transplant 1998;22:403-4.
205. Tse S, Saunders EF, Silverman E, et al. Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host disease. Bone Marrow Transplant 1999; 23:397-9.
206. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-3.
207. Lefvert AK, Bolme P, Hammarström L, et al. Bone marrow grafting selectively induces the production of acetylcholine receptor antibodies, immunoglobulins bearing related idiotypes, and antiidiotypic antibodies. Ann NY Acad Sci 1987;505:825-7.
208. Spritzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000;5:215-23.
209. Sykes M, Szof GL, Swenson KA, et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997;3:783-7.
210. Fändrich F, Lin X, Chai GX, et al. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 2002; 8:171-8.